Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 2, keine Gesamtzahl für „tenofovir disoproxil“
Suchtreffer
Begriffe & Kennungen
Efavirenz/Emtricitabine/Tenofovir disoproxil Krka · 4.1 Therapeutic indications · 1
Eintrag öffnenEfavirenz/Emtricitabine/Tenofovir disoproxil Krka · 4.3 Contraindications · 1
Eintrag öffnenEfavirenz/Emtricitabine/Tenofovir disoproxil Krka · 4.3 · Administration to patients with: - a family history of sudden death or of congenital prolongation of the QTc i
Eintrag öffnenEfavirenz/Emtricitabine/Tenofovir disoproxil Krka · 4.3 · Co administration with medicinal products that are known to prolong the QTc interval (proarrhythmic). These me
Eintrag öffnenEfavirenz/Emtricitabine/Tenofovir disoproxil Krka · 4.3 · Co-administration with elbasvir/grazoprevir due to the expected significant decreases in plasma concentrations
Eintrag öffnenEfavirenz/Emtricitabine/Tenofovir disoproxil Krka · 4.3 · Co-administration with herbal preparations containing St. John’s wort (Hypericum perforatum) due to the risk o
Eintrag öffnenEfavirenz/Emtricitabine/Tenofovir disoproxil Krka · 4.3 · Co-administration with terfenadine, astemizole, cisapride, midazolam, triazolam, pimozide, bepridil, or ergot
Eintrag öffnenEfavirenz/Emtricitabine/Tenofovir disoproxil Krka · 4.3 · Co-administration with voriconazole. Efavirenz significantly decreases voriconazole plasma concentrations whil
Eintrag öffnenEfavirenz/Emtricitabine/Tenofovir disoproxil Krka · 4.3 · Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.
Eintrag öffnenEfavirenz/Emtricitabine/Tenofovir disoproxil Krka · 4.3 · Severe hepatic impairment (CPT, Class C) (see section 5.2).
Eintrag öffnenEfavirenz/Emtricitabine/Tenofovir disoproxil Krka · 4.4 Special warnings and precautions for use · 1
Eintrag öffnenEfavirenz/Emtricitabine/Tenofovir disoproxil Krka · 4.5 Interaction with other medicinal products and other forms of interaction · 1
Eintrag öffnenEfavirenz/Emtricitabine/Tenofovir disoproxil Krka · 4.5 · 12 b.i.d./245 mg q.d.) be used with caution in Tenofovir: combination with *lower than recommended dose AUC: ↑
Eintrag öffnenEfavirenz/Emtricitabine/Tenofovir disoproxil Krka · 4.5 · 13 Cmax: ↔ efavirenz/emtricitabine/tenofovir Cmin: ↑ 51% (↑ 37 to ↑ 66) disoproxil is not recommended.
Eintrag öffnenEfavirenz/Emtricitabine/Tenofovir disoproxil Krka · 4.5 · 14 Saquinavir/ritonavir/Efavirenz Interaction not studied. For co- Insufficient data are available to administ
Eintrag öffnenEfavirenz/Emtricitabine/Tenofovir disoproxil Krka · 4.5 · 15 pathways. NNRTIs/Efavirenz Interaction not studied. Since use of two NNRTIs proved not beneficial in terms
Eintrag öffnenEfavirenz/Emtricitabine/Tenofovir disoproxil Krka · 4.5 · 16 decrease plasma concentrations of glecaprevir and pibrentasvir, leading to reduced therapeutic effect. Co-a
Eintrag öffnenEfavirenz/Emtricitabine/Tenofovir disoproxil Krka · 4.5 · 17 Cmax: ↔ Cmin: ↔
Eintrag öffnenEfavirenz/Emtricitabine/Tenofovir disoproxil Krka · 4.5 · 18 Rifabutin/Efavirenz Rifabutin: The daily dose of rifabutin should (300 mg q.d./600 mg q.d.) AUC: ↓ 38% (↓ 2
Eintrag öffnenEfavirenz/Emtricitabine/Tenofovir disoproxil Krka · 4.5 · 19 Posaconazole/Efavirenz Posaconazole: Concomitant use of posaconazole (-/400 mg q.d.) AUC: ↓ 50% and Cmax: ↓
Eintrag öffnen